Market Overview

Jefferies Reiterates Hold Rating, $6 PT for Exelixis

Related EXEL
16 Stocks Moving In Monday's Pre-Market Session
18 Biggest Mid-Day Losers For Friday
Exelixis +1.3%; mentioned in new article in Nature (Seeking Alpha)

In a company update published earlier today, Jefferies & Company, Inc. reiterated its Hold rating and $6.00 price target for Exelixis, Inc. (NASDAQ: EXEL), related to the recent reveal of cabo NRE efficacy data.

Jefferies went on to say “The cabo NRE data, somewhat key for the mCRPC outlook and presented at ASCO, left much to be desired. Despite somewhat intriguing early data in renal and liver cancers for which further exploration is warranted, we remain concerned about cabo's clinical, regulatory and commercial prospects in mCRPC, where investor and EXEL's focus lies.”

Exelixis, Inc. closed yesterday at $4.77.

Latest Ratings for EXEL

Aug 2016Stifel NicolausMaintainsBuy
Apr 2016Stifel NicolausUpgradesHoldBuy
Jan 2016Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for EXEL
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Reiteration Analyst Ratings


Related Articles (EXEL)

View Comments and Join the Discussion!